Measles vaccine — one versus two doses: why and when

  • J. Thipphawong
  • R. Wittes
  • O. Van-Ham


The decision to choose a two-dose measles vaccination schedule depends on whether elimination rather then control is the goal. Both mathematical models and epidemiologic observations suggest that elimination is not possible with only one dose of current measles vaccines. A two-dose schedule is clearly a minimum requirement for elimination. The decision to implement a second dose requires social and governmental acceptance of the need for elimination. The country must have both the desire to commit economic resources and the health care infrastructure to deliver the second dose. Decision makers must realize that it may require ten or more years to achieve elimination. A two-dose schedule will not prevent outbreaks, unless programs are in place to ensure high coverage with both doses. Poorly implemented programs will result in continued outbreaks and loss of public confidence in the strategy. It may be better to identify and vaccinate high-risk groups and thus ensure high first-dose coverage at an appropriate age, rather than to give 90% of the population two doses and 10% of the population no doses.


Vaccine Coverage Maternal Antibody Measle Vaccine Vaccination Schedule Measle Vaccination 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aaby P, Bukh J, LeerhøyJ, Lisse IM, Mordhorst CH, Pedersen IR (1986) Vaccinated children get milder measles infection: A community study from Guinea-Bissau. J Infect Dis 154(5): 858–863PubMedCrossRefGoogle Scholar
  2. 2.
    Aaby P, Jensen TG, Hansen HL, et al (1988) Trial of High-Dose Edmonston-Zangreb Vaccine in Guinea-Bissau: Protective Efficacy. Lancet II: 809–811CrossRefGoogle Scholar
  3. 3.
    Advisory Committee on Epidemiology (1991) Guidelines for Measles Control in Canada. Canad Dis Wkly Rep 17(7): 35–40Google Scholar
  4. 4.
    Advisory Committee on Immunisation Practices (1989) Measles Prevention: Recom mendations of the Immunization Practices Advisory Committee (ACIP). MMWR 38(S-9): 1–18Google Scholar
  5. 5.
    American Academy of Pediatrics (1989) Measles: Reassessment of the current immunization policy. Pediatrics 84(6): 1110–1113Google Scholar
  6. 6.
    Albrecht P, Ennis FA, Saltzman EJ, Krugman S (1977) Persistence of maternal antibody in infants beyond 12 months: Mechanism of measles vaccine failure. J Pediatr 91(5): 715–718PubMedCrossRefGoogle Scholar
  7. 7.
    Anderson RM, May RM (1990) Immunisation and herd immunity. Lancet II: 641–645CrossRefGoogle Scholar
  8. 8.
    Anderson RM (1992) The concept of herd immunity and the design of community-based immunization programmes. Vaccine 10(13): 928–935PubMedCrossRefGoogle Scholar
  9. 9.
    Anonymous (1985) Expanded program on immunization: European conference on immunization policies. Wkly Epidemiol Rec 60(22): 165–168Google Scholar
  10. 10.
    Anonymous (1986) Expanded programme on immunization, impact of immunization programme. Wkly Epidemiol Rec 29: 221–222Google Scholar
  11. 11.
    Anonymous (1987) Expanded programme on immunization, immunization coverage survey. Wkly Epidemiol Rec 25: 183–185Google Scholar
  12. 12.
    Anonymous (1988) Expanded programme on immunization, reported trends of EPI disease in Europe. Wkly Epidemiol Rec 12: 81–85Google Scholar
  13. 13.
    Anonymous (1988) Measles, measles elimination by 1990? Wkly Epidemiol Rec 22: 163–164Google Scholar
  14. 14.
    Anonymous (1989) Measles outbreak. (Hungary) Wkly Epidemiol Rec 18: 137–138Google Scholar
  15. 15.
    Anonymous (1990) Expanded programme on immunization, global advisory group, part I. Wkly Epidemiol Rec 2: 5–11Google Scholar
  16. 16.
    Anonymous (1990) Measles surveillance, outbreak of measles in a private international school in french-speaking Switzerland. Wkly Epidemiol Rec 23:173–175Google Scholar
  17. 17.
    Anonymous (1990) Expanded programme on immunization, measles outbreak. Wkly Epidemiol Rec 49: 379–381Google Scholar
  18. 18.
    Anonymous (1991) Expanded programme on immunization, safety and efficacy of high titre measles vaccine at 6 months of age. Wkly Epidemiol Rec 34: 249–251Google Scholar
  19. 19.
    Anonymous (1991) Measles surveillance 1982–1990. Wkly Epidemiol Rec 43: 314–317Google Scholar
  20. 20.
    Anonymous (1992) Expanded programme on immunization, global advisory group, part II. Wkly Epidemiol Rec 4: 17–19Google Scholar
  21. 21.
    Anonymous (1992) Expanded programme on immunization, measles epidemic, 1989–1990. Wkly Epidemiol Rec 8: 50–54Google Scholar
  22. 22.
    Anonymous (1992) Expanded programme on immunization, programme review. Wkly Epidemiol Rec 15: 109–111Google Scholar
  23. 23.
    Anonymous (1992) Measles outbreak in Bulgaria. Wkly Epidemiol Rec 12: 84–85Google Scholar
  24. 24.
    Anonymous (1992) Measles surveillance 1991-Austria & New Zealand. Wkly Epidemiol Rec 19: 139–142Google Scholar
  25. 25.
    Anonymous (1992) Seroepidemology of measles, mumps and rubella, Singapore. Wkly Epidemiol Rec 31: 231 -233Google Scholar
  26. 26.
    Anonymous (1992) Expanded programme on immunization. Safety on high titre measles vaccines. Wkly Epidemiol Rec 48: 357–361Google Scholar
  27. 27.
    Atkinson WL, Orenstein WA (1992) The resurgence of measles in the United States 1989–90. Annual Reviews of Medicine 43: 451–463CrossRefGoogle Scholar
  28. 28.
    Bart KJ, Orenstein WA, Hinman AR (1986) The Virtual Elimination of Rubella and Mumps from the United States and the Use of Combined Measles, Mumps and Rubella Vaccine (MMR) to Eliminate Measles. Devel Biol Stand 65: 45–52Google Scholar
  29. 29.
    Berry SB, Hernandez H, Kanoshiro R, et al (1992) Comparison of high titer Edmonston Zagreb, Biken-CAM and Schwarz measles vaccines in Peruvian infants. Pediatr Infect DisJ 11 (10): 822–827CrossRefGoogle Scholar
  30. 30.
    Black FL (1989) Measles. In: Evans AS (ed) Viral Infections of Humans: Epidemiology and Control Third Edition. Plenum Medical Book Company, New York and London, pp 451–469Google Scholar
  31. 31.
    Böttiger M, Christenson B, Romanus V, Taranger J, Strandell A (1987) Swedish experience of two dose vaccination programme aiming at eliminating measles, mumps, and rubella. Br Med J 295: 1264–1267CrossRefGoogle Scholar
  32. 32.
    Braunstein H, Thomas S, Ito R, et al (1991) Response of seronegative adults to measles immunization. Am J Dis Child 145:969PubMedGoogle Scholar
  33. 33.
    Brunell PA (1990) Measles control in the 1990s: Measles serology. WHO/EPI/GEN. 1–34Google Scholar
  34. 34.
    Bytchenko BD, Dittmann S (1986) Elimination of diseases from Europe through use of vaccines. Devel Biol Stand 65: 13–21Google Scholar
  35. 35.
    Bytchenko B, Prokhorskas R (1991) Regional immunization programme: Current and perspectives. ICP/EPI 027/20Google Scholar
  36. 36.
    Centers for Disease Control (1983) The feasibility of measles elimination in Europe. MMWR 32:523–4, 530Google Scholar
  37. 37.
    Centers for Disease Control (1991) Measles United States 1990. MMWE 40(22): 186–189Google Scholar
  38. 38.
    Chen RT, Goldbaum GM, Wassilak SGF (1989) An Explosive Point Source Measles Outbreak in a Highly Vaccinated Population. Am J Epidemiol 129(1): 173–181PubMedGoogle Scholar
  39. 39.
    Chen RT, Markowitz LE, Albrecht P, et al (1990) Measles antibody: Reevaluation of protective titers. J Infect Dis 162: 1036–1042PubMedCrossRefGoogle Scholar
  40. 40.
    Christenson B, Böttiger M (1991) Changes of the immunological patterns against measles, mumps and rubella. A vaccination programme studied 3 to 7 years after the introduction of a two-dose schedule. Vaccine 9: 326–329Google Scholar
  41. 41.
    Christenson B, Böttiger M, Heller L (1983) Mass vaccination programme aimed at eradicating measles, mumps, and rubella in Sweden: first experience. Br Med J 287:389–391CrossRefGoogle Scholar
  42. 42.
    Cutts FT (1990) Measles vaccination in early infancy and persistence of antibody (Letter). Lancet I: 913CrossRefGoogle Scholar
  43. 43.
    Cutts FT, Zell ER, Mason D et al (1992) Monitoring progress toward U.S. preschool immunization goals. JAMA 267(14): 1952–1955PubMedCrossRefGoogle Scholar
  44. 44.
    Dai Bin, Chem Zhihui, Wu Ting, et al (1991) Duration of immunity following immuni zation with live measles vaccine: 15 years of observation in Zhejiang Province, China. Bull WHO 69(4): 415–423PubMedGoogle Scholar
  45. 45.
    Davies JW, Acres SE, Varughese PV (1982) Experience with Measles in Canada and the United States. Canad Med Assoc J 126: 123–126PubMedGoogle Scholar
  46. 46.
    Edmonston MB, Addiss DG, McPherson JT, et al (1990) Mild measles and secondary vaccine failure during a sustained outbreak in a highly vaccinated population. JAMA 263(18):2467–247lCrossRefGoogle Scholar
  47. 47.
    Enders JF, Peebles TC (1954) Propagation in tissue cultures of cytopathic agents from patients with measles. Proc Soc Exp Biol Med 86: 277–286PubMedGoogle Scholar
  48. 48.
    Evans AS (1985) The eradication of communicable diseases: Myth or reality. Am J Epidemiol 122(2): 199–207PubMedGoogle Scholar
  49. 49.
    Fescharek R, Qµast U, Maass G, Merkle W, Schwarz S (1990) Measles-mumps vaccination in the FRG: an empirical analysis after 14 years of use. I. Efficacy and analysis of vaccine failures. Vaccine 8: 333–336Google Scholar
  50. 50.
    Fine PEM, ClarksonJA (1982) Measles in England and Wales I: An analysis of factors underlying seasonal patterns. Int J Epidemiol 11(1): 5–14PubMedCrossRefGoogle Scholar
  51. 51.
    Fine PEM, ClarksonJA (1982) Measles in England and Wales II: The impact of the measles vaccination programme on the distribution of immunity in the population. Int J Epidemiol 11(1): 15–25PubMedCrossRefGoogle Scholar
  52. 52.
    Frank JA, Orenstein WA, Bart KJ, et al (1985) Major impediments to measles elimina tion. Am J Dis Child 139: 881–888PubMedGoogle Scholar
  53. 53.
    Garenne M, Leroy O, Beau JP, et al (1991) Child mortality after high-titre measles vaccines: prospective study in Senegal. Lancet II: 903–906CrossRefGoogle Scholar
  54. 54.
    Ginsberg GM, Tulchinsky TH (1990) Costs and benefits of a second measles inoculation in Isreal, the West Bank, and the Gaza. J Epidemiology Community HealthGoogle Scholar
  55. 55.
    Goodwin S (1990) Preventive car for children: Immunization in England and Wales. Pediatrics 86(6)II: 1056–1060PubMedGoogle Scholar
  56. 56.
    Gustafson TL, Lievens AW, Brunnell PA (1987) Measles outbreak in a fully immunized secondary-school population. N Engl J Med 316:771–778PubMedCrossRefGoogle Scholar
  57. 57.
    Halsey NA (1983) The optimal age for administering measles vaccine in developing countries. In: Halsey NA, deQuadros CA (eds) Recent Advances in Immunization: A Bibliographic Review. Scientific Publication No. 451. PAHO:4–17Google Scholar
  58. 58.
    Hayden GF (1979) Measles Vaccine Failure. Clin Pediator 18(3): 163–167Google Scholar
  59. 59.
    Hersh BS, Markowitz LE, Maes EF (1992) The Geographic Distribution of Measles in the United States, 1980 Through 1989. JAMA 267(14): 1936–1941PubMedCrossRefGoogle Scholar
  60. 60.
    Hethcote HW (1983) Measles and Rubella in the United States. Am J Epidemiol 117:2–13PubMedGoogle Scholar
  61. 61.
    Hinman AR, Brandling-Bennett AD, Bernier RH et al (1980) Current features of measles in the United States: Feasibility of measles elimination. Epidemiologic Reviews 2:153–167PubMedGoogle Scholar
  62. 62.
    Hinman AR, Kirby CD, Eddins DL et al (1983) Elimination of indigenous measles from the United States. Rev Infect Dis 5(3): 538–545PubMedCrossRefGoogle Scholar
  63. 63.
    Hinman AR, Bart KJ, Hopkins DR (1985) Costs of not eradicating measles. Am J Publ Heal 75(7):713–4CrossRefGoogle Scholar
  64. 64.
    Hinman AR (1990) Immunization in the United States. Pediatrics 86(6)II: 1064–1066PubMedGoogle Scholar
  65. 65.
    Hirayama M (1983) Measles Vaccines Used in Japan. Rev Infect Dis 5(3): 495–503PubMedCrossRefGoogle Scholar
  66. 66.
    Kaplan LJ, Daum RS, Smaron M, et al (1992) Severe measles in immunocompromised patients. JAMA 267:1237–1241PubMedCrossRefGoogle Scholar
  67. 67.
    Krober MS, Stracener CE, Bass JW (1991) Decreased measles antibody response after measles-mumps-rubella vaccine in infants with colds. JAMA 265: 2095–2096PubMedCrossRefGoogle Scholar
  68. 68.
    Krugman S (1983) Further-attenuated measles vaccine: Characteristics and use. Rev Infect Dis 5(3): 477–481PubMedCrossRefGoogle Scholar
  69. 69.
    Lau Y, Chow C, Leung T (1992) Changing epidemiology of measles in Hong Kong from 1961 to 1990-Impact of a measles vaccination program. J Infect Dis 165:1111–1115PubMedCrossRefGoogle Scholar
  70. 70.
    Leese B, Bosanquet N (1992) Immunization in the UK: policy review and future economic options. Vaccine 10(8): 491–499PubMedCrossRefGoogle Scholar
  71. 71.
    Lett S, Scambio E, Spitalny K, et al (1991) Measles vaccination levels among selected groups of preschool-aged children United States. MMWR 40(2): 36–39Google Scholar
  72. 72.
    Levy D (1984) The Future of Measles in Highly Immunized Populations: A Modelling Approach. Am J Epidemiol 120(1): 39–48PubMedGoogle Scholar
  73. 73.
    Lievens AW, Brunell PA (1986) Specific immunoglobulin M enzyme-linked immunosorbent assay for confirming the diagnosis of measles. J Clin Microbiol 24(3): 391–394PubMedGoogle Scholar
  74. 74.
    Linnemann CC, Dine MS, Rosella GA, et al (1982) Measles immunity after revaccination: Results in children vaccinated before 10 months of age. Pediatrics 69:332PubMedGoogle Scholar
  75. 75.
    Makino S (1983) Development and Characteristics of Live AIK-G Measles Virus Vaccine: A Brief Report. Rev Infect Dis 5(3):504–505PubMedCrossRefGoogle Scholar
  76. 76.
    Markowitz LE, Preblud SR, Orenstein WA, et al (1989) Patterns of transmission in measles outbreaks in the United States, 1985–1986. N Engl J Med 320(2): 75–81PubMedCrossRefGoogle Scholar
  77. 77.
    Markowitz LE, Sepulueda J, Diaz-Ortega JL, et al (1990) Immunization of six-monthold infants with different doses of Edmonston-Zagreb and Schwarz measles vaccines. N Engl J Med 322: 580–587PubMedCrossRefGoogle Scholar
  78. 78.
    Markowitz LE (1990) Measles control in the 1990s: immunization before 9 months of age. WHO/EPI/90.3Google Scholar
  79. 79.
    Markowitz LE, Orenstein WA (1990) Measles vaccines. Ped Clinics of N America 37(3): 603–625Google Scholar
  80. 80.
    Markowitz LE, Preblud SR, Fine PEM, et al (1990). Duration of live measles vaccine-induced immunity. Pediatr Infect Dis J 9: 101–110PubMedCrossRefGoogle Scholar
  81. 81.
    Markowitz LE, Albrecht P, Orenstein WA, et al (1992) Persistence of Measles Antibody after Revaccination. J Infect Dis 166: 205–208PubMedCrossRefGoogle Scholar
  82. 82.
    Mary M, Garnerin P, Roure C, Villeminot S, Swartz TA, Valleron A (1992) Six years of public health surveillance of measles in France. Int J Epidemiol 21(1): 163–168PubMedCrossRefGoogle Scholar
  83. 83.
    Mathias RG, Meekison WG, Arcand TA, et al (1989) The role of secondary vaccine failures in measles outbreaks. Am J Publ Heal 79(4): 475–478CrossRefGoogle Scholar
  84. 84.
    Miller C (1987) Live measles vaccine: a 21 year follow up. Br Med J 295: 22–24CrossRefGoogle Scholar
  85. 85.
    National Advisory Committee on Immunization (1990) Statement on recommended use of measles vaccine in Canada. Canad Dis Wkly Rep 16(2): 7–10Google Scholar
  86. 86.
    National Vaccine Advisory Committee (1991) The Measles Epidemic; The Problems, Barriers and Recommedations. JAMA 266(11): 1547–1552CrossRefGoogle Scholar
  87. 87.
    Nkowane BM, Bart SW, Orenstein WA, et al (1987) Measles outbreak in a vaccinated school population; epidemiology, chains of transmission and the role of vaccine failures. Am J Publ Heal 77(4): 434–438CrossRefGoogle Scholar
  88. 88.
    Nokes DJ, Anderson RM (1988) Measles, mumps and rubella vaccines: What coverage to block transmission? Lancet II: 1374CrossRefGoogle Scholar
  89. 89.
    Nokes DJ, McLean AR, Anderson RM, Grabowsky M (1990) Measles immunization strategies for countries with high transmission rates: Interim guidelines predicted using a mathematical model. Int J Epidemiol 19(3): 703–710PubMedCrossRefGoogle Scholar
  90. 90.
    Norrby E, Oxman MN (1990) Measles virus. In: Fields BN (ed) Virology, Raven Press Ltd., New York, 1013–1044Google Scholar
  91. 91.
    Orenstein WA, Markowitz L, Preblud SR (1986) Appropriate age for measles vaccina tion in the United States. Devel Biol Stand 65: 13–21Google Scholar
  92. 92.
    Osterman JW, Melnychuk D (1992) Revaccination of children during school based measles outbreaks: Potential impact of a new policy recommendation. Canad Med AssocJ 146(6): 929–936Google Scholar
  93. 93.
    Pabst HF, et al (1992) Reduced measles immunity in infants in a well-vaccinated population. Pediatr Infect Dis J 11(7): 525–529PubMedCrossRefGoogle Scholar
  94. 94.
    Pan American Health organization (1992) Measles elimination in the Americas. Bulletin of PAHO 26(3): 271–274Google Scholar
  95. 95.
    Parkman PD, Hopps HE, Albrecht P, et al (1983) Simultaneous Adminstration of Vaccines. Biographic Reviews PAHO. 65–80Google Scholar
  96. 96.
    Paunio M, Virtanen M, Peltola H, Cantell K, Paunio P, Valle M, Karanko V, Heinonen OP (1991) Increase of vaccination coverage by mass media and individual approach: Intensified measles, mumps and rubella prevention program in Finland. Am J Epidemiol 133(11): 1152–1160PubMedGoogle Scholar
  97. 97.
    Peltola H, Karanko V, Kurki T, Hukkanen V, Virtanen M, Penttinen K, Nissinen M, Heinonen OP (1986) Rapid effect on endemic measles, mumps, and rubella of nationwide vaccination programme in Finland. Lancet I: 137–139CrossRefGoogle Scholar
  98. 98.
    Peradze TV, Smorodintsev AA (1983) Epidemiology and specific prophylaxis of measles. Rev Infect Dis 5(3): 487–490PubMedCrossRefGoogle Scholar
  99. Personal Communication from Dr. Max Just, Badler Kinderspital, Basel, SwitzerlandGoogle Scholar
  100. Personal Communication from Odile Leroy, Pasteur Mérieux S.V., Marne La Coquette, FranceGoogle Scholar
  101. 101.
    Pontecorvo M (1990) Vaccini Sieri Immunoglobuline: Prontuario per l’uso. VI Edizione. Edizioni Minerva Medica, TorinoGoogle Scholar
  102. 102.
    Prebuld SR, Katz SL (1988) Measles Vaccine. In: Plotkin SA, Mortimer EA (ed) Vaccines. W.B Saunders Company. Philadelphia, pp 182–222Google Scholar
  103. 103.
    Rabo E, Taranger J (1984) Scandinavian model for eliminating measles, mumps, and rubella. Br Med J 289: 1402–1404CrossRefGoogle Scholar
  104. 104.
    Reyes MR, De Borrero MF, Roa J, etal (1987) Measles vaccine failure after documented seroconversion. Ped Infect Dis J 6(9): 848–851CrossRefGoogle Scholar
  105. 105.
    Rossier E, Miller H, McCulloch B, (1992) Measles in Ontario. PHERO 3(8): 125–128Google Scholar
  106. 106.
    Sejda J (1979) Evaluation of the eight-year period of compulsory measles vaccintion in the Czech Socialist Republic (CSR). J Hyg Epidemiol Microbiol Immunol 23(3): 273–283PubMedGoogle Scholar
  107. 107.
    Sejda J (1983) Control of Measles in Czechoslovakia (CSSR). Rev Infect Dis 5(3): 564–567PubMedCrossRefGoogle Scholar
  108. 108.
    Stetler HC, Orenstein WA, Bernier RH (1986) Impact of revaccination on children who initially received measles vaccine before 10 months of age. Pediatrics 77:471PubMedGoogle Scholar
  109. 109.
    Taylor WR, Mambu R, Weinman JM (1988) Measles control efforts in urban Africa complicated by high incidence of measles in the first year of life. Am J Epidemiol 127:788–794PubMedGoogle Scholar
  110. 110.
    Thacker SB, Millar JD (1991) Mathematical modeling and attempts to eliminate measles: A tribute to the late professor George Macdonald. Am J Epidemiol 133(6): 517–525PubMedGoogle Scholar
  111. 111.
    Tidjani O, Grunitsky B, Guerin N, etal (1989) Serological effects of Edmonston Zagreb, Schwarz, and AIK-C measles vaccine strains given at ages 4–5 or 8–10 months. Lancet II: 1357–1360CrossRefGoogle Scholar
  112. 112.
    Friedman JB, Schoenbaum ML, Slater PE (1990) Measles in Israel, the West Bank, and Gaza: Continuing incidence and the case for a new eradication strategy. Rev Infect Dis 12(5): 951–958PubMedCrossRefGoogle Scholar
  113. 113.
    Verbrugge HP (1990) The national immunization program of the Netherlands. Pediatrics 86(6)II: 1060–1063PubMedGoogle Scholar
  114. 114.
    White CC, Koplan JP, Orenstein WA (1985) Benefits, Risks and Costs of Immunization for Measles, Mumps and Rubella. Am J Publ Heal 75(7): 739–744CrossRefGoogle Scholar
  115. 115.
    White FM (1983) Policy for measles elimination in Canada and program implications. Rev Infect Dis 5(3): 577–582PubMedCrossRefGoogle Scholar
  116. 116.
    Whittle HC, Rowland MG, Mann GF, et al (1984) Immunization of 4–6 month old Gambian infants with Edmonston-Zagreb measles vaccine. Lancet 11:834–837CrossRefGoogle Scholar
  117. 117.
    Whittle HC, Mann G, Eccles M, et al (1988) Effects of dose and strain of vaccine on success of measles vaccination of infants aged 4–+5 months. Lancet I:963–966CrossRefGoogle Scholar
  118. 118.
    Whittle HC, Campbell H, Rahman, S, et al (1990) Antibody persistance in Gambian children after high-dose Edmonston-Zagreb measles vaccine. Lancet II: 1046–1048CrossRefGoogle Scholar
  119. 119.
    Williams BC (1990) Immunization coverage among preschool children: The United States and selected European countries. Pediatrics 86(6)II: 1052–1056PubMedGoogle Scholar
  120. 120.
    Williams PJ, Hull HF (1983) Status of measles in the Gambia, 1981. Rev Infect Dis 5(3): 391–394PubMedCrossRefGoogle Scholar
  121. 121.
    Xiangjianzhi, Chen Zhihui (1983) Measles Vaccine in the People’s Republic of China. Rev Infect Dis 5(3): 506–510CrossRefGoogle Scholar
  122. 122.
    Yekutiel P (1981) Lessions from the big eradication campaigns. World Health Forum 2(4): 465–490Google Scholar

Copyright information

© Springer-Verlag/Wien 1993

Authors and Affiliations

  • J. Thipphawong
    • 1
  • R. Wittes
    • 1
  • O. Van-Ham
    • 1
  1. 1.Connaught Laboratories LimitedWillowdaleCanada

Personalised recommendations